⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for monalizumab (iph2201)

Every month we try and update this database with for monalizumab (iph2201) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceNCT03833440
Non-small Cell ...
Durvalumab (MED...
Monalizumab (IP...
Oleclumab (MEDI...
Ceralasertib (A...
DOCETAXEL
Savolitinib
18 Years - Assistance Publique Hopitaux De Marseille
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceNCT03833440
Non-small Cell ...
Durvalumab (MED...
Monalizumab (IP...
Oleclumab (MEDI...
Ceralasertib (A...
DOCETAXEL
Savolitinib
18 Years - Assistance Publique Hopitaux De Marseille
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceNCT03833440
Non-small Cell ...
Durvalumab (MED...
Monalizumab (IP...
Oleclumab (MEDI...
Ceralasertib (A...
DOCETAXEL
Savolitinib
18 Years - Assistance Publique Hopitaux De Marseille
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: